In addition, downregulating the expression of TGF-β in tumors by oncolytic adenovirus targeting TGF-β demonstrated enhanced anti-PD-1 and anti-CTLA-4 therapeutic effects in animal models of kidney cancer and breast cancer [54]. The gene discussed is TGFB1; the disease is breast carcinoma.